Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
Tikvah Management , owning approximately 1.5% of Quanterix Corp. (QTRX), has expressed serious concerns regarding Quanterix's recent agreement to purchase up to $30 million in convertible notes from Akoya Biosciences (AKYA).
The investment firm highlighted three major concerns: 1) Akoya's need for bridge financing indicates potential financial distress, 2) the timing of the capital commitment before the shareholder vote on the proposed Quanterix-Akoya merger is questionable, and 3) the convertible notes' terms are considered unfavorable to Quanterix shareholders.
Tikvah has reaffirmed its intention to vote AGAINST the proposed merger between Quanterix and Akoya at the upcoming Special Meeting, while reserving the right to change its position based on new developments.
Tikvah Management, che detiene circa l'1,5% di Quanterix Corp. (QTRX), ha espresso serie preoccupazioni riguardo all'accordo recente di Quanterix per l'acquisto di fino a 30 milioni di dollari in note convertibili da Akoya Biosciences (AKYA).
L'azienda di investimento ha evidenziato tre principali preoccupazioni: 1) la necessità di finanziamenti ponte da parte di Akoya indica un potenziale disagio finanziario, 2) il tempismo dell'impegno di capitale prima del voto degli azionisti sulla proposta di fusione Quanterix-Akoya è discutibile, e 3) i termini delle note convertibili sono considerati sfavorevoli per gli azionisti di Quanterix.
Tikvah ha ribadito la sua intenzione di votare CONTRO la fusione proposta tra Quanterix e Akoya nella prossima Assemblea Straordinaria, riservandosi il diritto di cambiare posizione in base a nuovi sviluppi.
Tikvah Management, que posee aproximadamente el 1.5% de Quanterix Corp. (QTRX), ha expresado serias preocupaciones con respecto al reciente acuerdo de Quanterix para comprar hasta 30 millones de dólares en notas convertibles de Akoya Biosciences (AKYA).
La firma de inversión destacó tres preocupaciones principales: 1) la necesidad de financiamiento puente por parte de Akoya indica un posible estrés financiero, 2) el momento del compromiso de capital antes de la votación de los accionistas sobre la propuesta de fusión Quanterix-Akoya es cuestionable, y 3) los términos de las notas convertibles se consideran desfavorables para los accionistas de Quanterix.
Tikvah ha reafirmado su intención de votar EN CONTRA de la fusión propuesta entre Quanterix y Akoya en la próxima Junta Especial, reservándose el derecho de cambiar su posición en función de nuevos desarrollos.
틱바 관리는 퀀터릭스 코퍼레이션 (QTRX)의 약 1.5%를 소유하고 있으며, 퀀터릭스가 아코야 바이오사이언스 (AKYA)로부터 최대 3천만 달러의 전환사채를 구매하기로 한 최근 계약에 대해 심각한 우려를 표명했습니다.
투자 회사는 세 가지 주요 우려 사항을 강조했습니다: 1) 아코야의 브리지 자금 조달 필요성은 잠재적인 재정적 어려움을 나타냅니다, 2) 퀀터릭스-아코야 합병 제안에 대한 주주 투표 전에 자본 약속의 타이밍이 의문스럽습니다, 3) 전환사채의 조건은 퀀터릭스 주주에게 불리한 것으로 간주됩니다.
틱바는 다가오는 특별 회의에서 퀀터릭스와 아코야 간의 제안된 합병에 반대하여 투표할 의사를 재확인했으며, 새로운 발전에 따라 입장을 변경할 권리를 보유하고 있습니다.
Tikvah Management, qui possède environ 1,5% de Quanterix Corp. (QTRX), a exprimé de sérieuses inquiétudes concernant l'accord récent de Quanterix pour acheter jusqu'à 30 millions de dollars de billets convertibles auprès de Akoya Biosciences (AKYA).
La société d'investissement a souligné trois préoccupations majeures : 1) le besoin de financement relais d'Akoya indique un potentiel stress financier, 2) le moment de l'engagement de capital avant le vote des actionnaires sur la fusion proposée Quanterix-Akoya est discutable, et 3) les conditions des billets convertibles sont considérées comme défavorables pour les actionnaires de Quanterix.
Tikvah a réaffirmé son intention de voter CONTRE la fusion proposée entre Quanterix et Akoya lors de la prochaine Assemblée Générale Extraordinaire, tout en se réservant le droit de changer de position en fonction des nouveaux développements.
Tikvah Management, das etwa 1,5% von Quanterix Corp. (QTRX) besitzt, hat ernsthafte Bedenken hinsichtlich der jüngsten Vereinbarung von Quanterix geäußert, bis zu 30 Millionen Dollar an wandelbaren Anleihen von Akoya Biosciences (AKYA) zu kaufen.
Die Investmentfirma hat drei Hauptbedenken hervorgehoben: 1) Der Finanzierungsbedarf von Akoya deutet auf mögliche finanzielle Schwierigkeiten hin, 2) der Zeitpunkt des Kapitalengagements vor der Aktionärsversammlung zur vorgeschlagenen Fusion von Quanterix und Akoya ist fragwürdig, und 3) die Bedingungen der wandelbaren Anleihen gelten als nachteilig für die Quanterix-Aktionäre.
Tikvah hat bekräftigt, dass sie bei der bevorstehenden außerordentlichen Hauptversammlung GEGEN die vorgeschlagene Fusion zwischen Quanterix und Akoya stimmen wird, behält sich jedoch das Recht vor, ihre Position basierend auf neuen Entwicklungen zu ändern.
- None.
- Akoya shows signs of financial distress requiring bridge financing
- Convertible notes terms deemed unfavorable to Quanterix shareholders
- Significant shareholder opposition to the merger (1.5% stakeholder voting against)
- Questionable timing of capital commitment before shareholder approval
Tikvah’s statement follows:
“This announcement concerns us for several reasons. First, we believe Akoya’s need to obtain bridge financing serves as a significant warning sign of its financial distress. Second, we find it both unusual and coercive to Quanterix’s shareholders that this capital is being committed before a shareholder vote on the Company’s proposed merger with Akoya. Lastly, the terms of these convertible notes are significantly off market and unfair to Quanterix shareholders. Quanterix owes shareholders an explanation as to why it has put its investors in such a seemingly disadvantaged position.”
Tikvah reiterates its previous statement and continues to plan to vote AGAINST Quanterix’s proposed merger with Akoya at the upcoming Quanterix Special Meeting for shareholders. Tikvah reserves the right to change its intention should there be new developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414697126/en/
Media Contact:
Josh Kuckley
980 433 1057
jk@simcah.com
Source: Tikvah Management LLC
FAQ
Why is Tikvah Management opposing Quanterix's (QTRX) convertible note purchase from Akoya?
What is the value of the convertible notes agreement between Quanterix (QTRX) and Akoya?
How much of Quanterix (QTRX) does Tikvah Management own?
How does Tikvah Management plan to vote on the Quanterix-Akoya merger?
